Horizon Pharma Inc. Hits New 52-Week High at $10.52 (HZNP)
Shares of Horizon Pharma (NASDAQ:HZNP) hit a new 52-week high during trading hours on Wednesday, AR Network reports. The company traded as high as $10.52 and last traded at $10.27, with a volume of 6,833,694 shares trading hands. The stock had previously closed at $8.50.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Horizon Pharma from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, January 7th. They now have a $8.80 price target on the stock. Separately, analysts at Piper Jaffray reiterated a “buy” rating on shares of Horizon Pharma in a research note to investors on Wednesday, November 20th. They now have a $7.00 price target on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Horizon Pharma from $7.00 to $10.00 in a research note to investors on Wednesday, November 20th. They now have a “buy” rating on the stock. Six research analysts have rated the stock with a buy rating, Horizon Pharma currently has an average rating of “Buy” and an average target price of $8.63.
Horizon Pharma has a one year low of $1.97 and a one year high of $9.13. The stock’s 50-day moving average is $7.8 and its 200-day moving average is $4.69. The company’s market cap is $669.8 million.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.03) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.25) by $0.22. The company had revenue of $31.50 million for the quarter, compared to the consensus estimate of $18.31 million. During the same quarter in the prior year, the company posted ($0.47) earnings per share. On average, analysts predict that Horizon Pharma will post $-0.85 earnings per share for the current fiscal year.
Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.